Evidence map›Paper›PMID 32997666›Full record

Trial reportPLoS neglected tropical diseases2020

Validation of the Micronutrient and Environmental Enteric Dysfunction Assessment Tool and evaluation of biomarker risk factors for growth faltering and vaccine failure in young Malian children.

Michael B Arndt, Jason L Cantera, Laina D Mercer, Michael Kalnoky, Heather N White, Gregory Bizilj, David S Boyle, Eugenio L de Hostos, Robert K M Choy

Open access · goldAbstract readClinical Trial, Phase IVRandomized Controlled Trial
In one paragraph

Trial report in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Natural history and impact ofmedRxiv : the preprint server for health sciences · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Michael B ArndtPATH, Seattle, Washington, United States of America.ORCID 0000-0001-9063-0644
Jason L CanteraPATH, Seattle, Washington, United States of America.
Laina D MercerPATH, Seattle, Washington, United States of America.ORCID 0000-0002-2517-8900
Michael KalnokyPATH, Seattle, Washington, United States of America.
Heather N WhitePATH, Seattle, Washington, United States of America.
Gregory BiziljPATH, Seattle, Washington, United States of America.
David S BoylePATH, Seattle, Washington, United States of America.
Eugenio L de HostosPATH, Seattle, Washington, United States of America.
Robert K M ChoyPATH, Seattle, Washington, United States of America.ORCID 0000-0002-8441-4029
Program for Appropriate Technology in Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Environmental enteric dysfunction (EED) is an intestinal disorder common among children in low-resource settings and is associated with increased risk of growth stunting, cognitive deficits, and reduced oral vaccine immunogenicity. The Micronutrient and EED Assessment Tool (MEEDAT) is a multiplexed immunoassay that measures biomarkers previously associated with child growth faltering and/or oral vaccine immunogenicity: intestinal fatty acid-binding protein (I-FABP), soluble CD14 (sCD14), insulin-like growth factor 1 (IGF-1), and fibroblast growth factor 21 (FGF21). MEEDAT also measures systemic inflammation (α1-acid glycoprotein, C-reactive protein), ferritin, soluble transferrin receptor, retinol binding protein 4, thyroglobulin, and Plasmodium falciparum antigenemia (histidine-rich protein 2). The performance of MEEDAT was compared with commercially available enzyme-linked immunosorbent assays (ELISAs) using 300 specimens from Malian infant clinical trial participants. Regression methods were used to test if MEEDAT biomarkers were associated with seroconversion to meningococcal A conjugate vaccine (MenAV), yellow fever vaccine (YFV), and pentavalent rotavirus vaccine (PRV) after 28 days, or with growth faltering over 12 weeks. The Pearson correlations between the MEEDAT and ELISA results were 0.97, 0.86, 0.80, and 0.97 for serum I-FABP, sCD14, IGF-1, and FGF21, respectively. There were significant associations between I-FABP concentration and the probability of PRV IgG seroconversion and between IGF-1 concentration and the probability of YFV seroconversion. In multivariable models neither association remained significant, however there was a significant negative association between AGP concentration and YFV seroconversion. GLP-2 and sCD14 concentrations were significantly negatively associated with 12-week change in weight-for-age z-score and weight-for-height z-score in multivariable models. MEEDAT performed well in comparison to commercially-available ELISAs for the measurement of four analytes for EED and growth hormone resistance. Adoption of MEEDAT in low-resource settings could help accelerate the identification of interventions that prevent or treat child stunting and interventions that boost the immunogenicity of child vaccinations.

Indexed as

BiomarkersDouble-Blind MethodEnzyme-Linked Immunosorbent AssayFatty Acid-Binding ProteinsFemaleFerritinsFibroblast Growth FactorsHumansImmunogenicity, VaccineInfantInflammationInsulin-Like Growth Factor IIntestinal DiseasesIntestine, SmallLipopolysaccharide ReceptorsMaleBiomarkersCD14 protein, humanFABP2 protein, humanFatty Acid-Binding ProteinsFerritinsFGF21 protein, humanFibroblast Growth FactorsIGF1 protein, humanInsulin-Like Growth Factor ILipopolysaccharide ReceptorsMicronutrientsRBP4 protein, humanRetinol-Binding Proteins, PlasmaVaccinesYellow Fever Vaccine

Identifiers

PMID32997666
PMCPMC7549819
OpenAlexW3089641354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.